Browsing Tag
psoriasis
10 posts
Zasocitinib meets all endpoints in Phase 3 trials, Takeda (NYSE: TAK) eyes FDA submission in 2026
Takeda’s once-daily TYK2 pill hits PASI 100 in Phase 3 psoriasis trials. Find out what this means for rivals, regulators, and Takeda’s pipeline strategy.
Innovent Biologics achieves key milestone as PECONDLE delivers sustained efficacy in Phase 3 psoriasis trial
Find out how Innovent’s PECONDLE is redefining long-term psoriasis care with sustained response and quarterly dosing.
Can psoriatic disease remission be redefined? Inside the shift toward zero activity in targeted domains
Discover how zero disease activity in one or more domains is reshaping psoriatic care, pharma strategy, and future treatment benchmarks.
Can-Fite submits pediatric plan to FDA for Piclidenoson in psoriasis treatment
Biotech leader Can-Fite BioPharma, known for its advances in oncology, inflammatory, and liver diseases, has taken a significant…
Biocon Biologics signs licensing deal for two biosimilars with Yoshindo
Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo…
Lupin secures Health Canada approval for Enbrel biosimilar – Rymti
Lupin Limited has secured approval from Health Canada for Rymti, the company’s biosimilar to Enbrel (etanercept), an inhibitor…
Strides Pharma gets FDA approval for Cyclosporine Softgel Capsules
Strides Pharma Science said that its stepdown fully-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has secured approval…
Can Glenmark Pharmaceuticals’ FDA approval for Enstilar Foam generic boost its U.S. dermatology footprint?
Glenmark Pharmaceuticals secures FDA approval for its generic version of Enstilar Foam, aiming to expand its U.S. dermatology market presence.
Mylan launches Hulio, a biosimilar to Humira, across major European markets
Mylan has officially launched Hulio, its biosimilar to AbbVie’s Humira (adalimumab), across major European markets. This launch follows…
Boehringer Ingelheim’s Cyltezo achieves clinical equivalence to Humira in Phase 3 psoriasis trial
German pharmaceutical giant Boehringer Ingelheim has announced a significant milestone in the treatment of moderate-to-severe chronic plaque psoriasis.…